LLY News and Press, Eli Lilly and Company From 05/02/24

2024-05-02 05:45:00 ET Shares of Eli Lilly and Company (NYSE: LLY) have soared nearly 35% so far in 2024 and are only a few points away from doubling over the last 12 months. The company reigns as the biggest drugmaker in the world based on market cap. It's also the largest company ...

2024-05-02 04:11:57 ET More on Novo Nordisk Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy Novo Nordisk Remains The Better Buy After A Moderate Pullback Novo Nordisk: The Moat Won't Last Forever Novo Nordisk reports Q1 results; update...

2024-05-01 17:07:44 ET Summary Amgen Inc. shares have dropped some 20% since reaching an all-time high in February due to a below-consensus outlook and patent concerns. The company's four pillars of growth are General Medicine, Oncology, Inflammatory Diseases, and Rare Diseases. ...

2024-05-01 14:41:05 ET Summary Eli Lilly and Company's revenue for the first quarter of 2024 fell short of analysts' expectations, but the company exceeded forecasts on the bottom line. Sales of the company's obesity and diabetes drugs, particularly Mounjaro and Zepbound, saw sign...

2024-05-01 13:09:30 ET Summary NVIDIA and Eli Lilly are driving the bull market with their breakthrough technologies in AI and GLP-1s, respectively. LLY's strong Q1 and increased guidance suggest it could reach a $1 trillion market cap in the coming quarters if the company continu...

2024-05-01 12:44:46 ET Summary Eli Lilly reported strong Q1 results, with a 26% increase in revenues and a 59% increase in non-GAAP EPS. Management increased revenue guidance for 2024 due to strength in the GLP-1 franchise. Lilly's impressive pipeline includes potential treatm...

2024-05-01 11:00:12 ET Summary Eli Lilly and Company missed sales targets by $160 million in Q1 despite strong growth in diabetes and weight loss drugs. The drug company provided strong guidance for 2024 due to higher drug production capacity in the 2H. Eli Lilly stock is alre...

2024-05-01 10:00:07 ET Evan Seigerman from BMO Capital issued a price target of $1,001.00 for LLY on 2024-05-01 08:55:00. The adjusted price target was set to $1,001.00. At the time of the announcement, LLY was trading at $781.1. The overall price target consensus is at ...

2024-05-01 07:15:09 ET Barclays analyst issues OVERWEIGHT recommendation for LLY on May 1, 2024 05:12AM ET. The previous analyst recommendation was Overweight. LLY was trading at $781.1 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curr...

2024-05-01 06:01:13 ET Pfizer ( NYSE: PFE ) is reportedly developing a direct-to-consumer (DTC) platform to sell drugs directly to patients.... Read the full article on Seeking Alpha For further details see: Pfizer plans direct-to-consumer platform to sell Covid, mig...